<DOC>
	<DOCNO>NCT00592124</DOCNO>
	<brief_summary>A new approach HIV prevention currently study include use microbicides , substance kill microbe . Tenofovir disoproxil fumarate ( TDF ) oral , FDA-approved , anti-HIV drug , tenofovir gel experimental microbicide . The purpose study determine adherence acceptability blood level three daily regimen tenofovir oral gel form .</brief_summary>
	<brief_title>Adherence Acceptability Blood Levels Tenofovir Gel Tablets HIV Uninfected Women</brief_title>
	<detailed_description>It necessary monitor adherence blood level microbicides order gauge efficacy study population . Utilizing experimental microbicide ( tenofovir gel ) anti-HIV drug ( TDF ) , study measure adherence acceptability blood level two intervention three separate regimen give HIV-uninfected woman . The expected duration participation participant 21 week . Study participant randomly assign one six study group , different regimen sequence . Each sequence consist three study period three wash-out period . Each study period last 6 week , follow 1 week wash-out period . The regimen assign give study period include either oral TDF , tenofovir vaginal gel , . All participant prescribe three regimen order designate randomized assignment . Study visit occur Weeks 1 , 3 , 6 , 7 , 10 , 13 , 14 , 17 , 20 , 21 . Medical history , physical exam , behavioral assessment , urine , blood , pelvic sample collection , counsel occur visit . At study site rectal swab may perform . Counseling include information regard contraception , protocol adherence , HIV , HIV/Sexually Transmitted Infection risk reduction , male condom use . Pharmacokinetic ( PK ) study , determine study site , occur three study period . These study may involve additional procedure .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>General good health HIVuninfected Normal menstrual cycle . More information find protocol . Creatinine clearance great 70 ml/min Sexually active . More information find protocol . Normal Pap smear result within 12 month prior study entry Agrees participate investigational study Willing use effective form contraception . More information find protocol . Adverse reaction either study product Adverse reaction latex Currently sexually active partner history adverse reaction latex More three sexual partner month prior screen Pathologic bone fracture relate trauma Last pregnancy outcome within 90 day less prior enrollment Gynecologic genital procedure within 90 day study entry Enrollment investigational study within 30 day study entry Nontherapeutic injection drug use within 12 month screen Any social medical condition , opinion investigator , would interfere study Abnormal laboratory value Grade 2 high genital lesion , erythema , and/or edema abnormal physical pelvic exam finding , opinion investigator , would interfere study Kidney , reproductive , urinary tract infection require treatment . More information criterion find protocol . Pregnant , breastfeeding , intend become pregnant Unwilling comply study participation requirement , include attendance schedule study visit Per participant report , use follow enrollment , and/or anticipate use period study participation use diaphragm , vaginal ring , and/or spermicide contraception , acyclovir valacyclovir , postexposure prophylaxis HIV exposure , TDF/emtricitabine , nonstudy vaginal product</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>